



Pharma **POOL**

Dr. Nancy

JOSEPH-RIDGE

Alan **MACKENZIE**

Takeda Unveils Post-TAP Executive Structure

Takeda Pharmaceuticals North America (TPNA), Deerfield, Ill., has announced leadership changes as part of the closing of TAP Pharmaceutical Products, the U.S.-based joint venture between Abbott Laboratories and TPNA's Japanese parent, Takeda Pharmaceutical Co. Ltd.

Nancy Joseph-Ridge, M.D., formerly VP of research and development at TAP, has been appointed president of Takeda Global Research & Development Center (TGRD). Before joining TAP in 2002, Dr. Joseph-Ridge worked in drug safety and clinical development at Searle, now part of Pfizer. She received an M.D. from the University of Illinois at Chicago.

Alan MacKenzie, formerly president of TAP and a president of TPNA, has been named executive VP of Takeda America Holdings (TAH) and CEO of TPNA. TPNA president Mark Booth is remaining with the company temporarily to support integration activities following the closure of the TAP transaction.

Mr. MacKenzie joined TAP in 1985 as a sales representative. He received a BSN from Wagner College, a B.A. in economics from City University of New York, and an MBA from the University of Chicago.

Robert **LAVERTY**

Eisai Appoints Communications VP

Eisai Corporation of North America,

Woodcliff Lake, N.J., has named Robert Laverty to the newly created position of VP of U.S. corporate communications. Mr. Laverty was most recently VP, global communications, malaria initiatives, for Novartis. He received a B.S. in pharmacy from St. John's University.

Paul **ROMNESS**

Dr. Philip **VICKERS**

Boehringer Ingelheim Adds to Executive Team



Boehringer Ingelheim, Ridgefield, Conn., has appointed Paul Romness VP of government affairs and public policy. Mr. Romness' responsibilities include executing plans at the federal and state levels through the development of regulation, legislation, and policy, as well as leading the management of the Boehringer Ingelheim Cares Patient Assistance Program, the Boehringer Ingelheim Product Donation Program, and the Boehringer Ingelheim Corporation Political Action Committee (BIC-PAC).

Most recently, Mr. Romness was principal at PR Strategies. He received a B.S. in finance from American University and a master's in health policy from George Washington University Medical Center.



Philip Vickers, Ph.D., has joined Boehringer Ingelheim as senior VP of research. Dr. Vickers is responsible for overseeing research activities at Boehringer Ingelheim's U.S. headquarters and is also a member of the German company's global research leadership team.

Most recently, Dr. Vickers served as VP of global research and development at Pfizer and site head of the Pfizer Research Technology Center in Cambridge, Mass. He received a B.S. in applied biochemistry from the University of Salford in Manchester, United Kingdom, and a Ph.D. in biochemistry from the University of Toronto.

Biotech **POOL**

Dr. Gordon **PARRY**

Monogram Biosciences Promotes Research VP



Monogram Biosciences, South San Francisco, Calif., has promoted Gordon Parry, Ph.D., to VP, research and development, oncology, from senior director of research and development, oncology. Dr. Parry is responsible for Monogram's oncology R&D programs, including further development of Monogram's proprietary VeraTag technology platform and the first product based on that platform, the HERMark Breast Cancer Assay.

Dr. Parry received a Ph.D. in biochemistry from the University of London.

Dr. Parry received a Ph.D. in biochemistry from the University of London.

Biopharmaceutical **POOL**

Randall **ST. LAURENT**

ARCA Shifts Focus to Commercialization

ARCA Discovery, Denver, has changed its name to ARCA biopharma to reflect its focus on the commercialization of its cardiovascular drug candidates.

As part of this transformation, the company has appointed Randall St. Laurent executive VP of commercial operations, with initial responsibility for supporting the approval application for ARCA's lead product, the next-generation beta-blocker and vasodilator bucindolol.

Mr. St. Laurent was most recently VP of commercial development at Scios. He received a bachelor's degree with a major in marketing from The Ohio State University.

Specialty **POOL**Dr. Ernie **BICZAK**Richard **DESIMONE**Stephen **HULSE**Dave **IWANICKI**Dr. Tong **ZHANG****EKR Therapeutics Adds to Management Team**

EKR Therapeutics, Cedar Knolls, N.J., a specialty pharmaceutical company focused on acute-care products, has made a number of additions to its executive team.

Ernie Biczak, M.D., has joined EKR as senior VP of marketing, from Esprit Pharma, where he served as executive VP, medical affairs. He received an M.D. from Rutgers Medical School.

EKR cofounder Richard DeSimone has been named chief operating officer. Mr. DeSimone previously served as chief financial officer and a company director.

Stephen Hulse, R.Ph., has been named VP of sales. Mr. Hulse was most recently director of sales, central area, for PDL BioPharma. He is a graduate of Albany College of Pharmacy, Union University.

Dave Iwanicki has joined EKR as senior VP of commercial operations from PDL BioPharma, where he was VP, sales, and sales operations and corporate officer. He received a B.S. in business administration from Western New England College.

Tong Zhang, Ph.D., has been promoted to VP of business development. Since joining EKR in early 2007, Dr. Zhang's responsibilities have centered on pursuing opportunities to leverage EKR's commercial organization. He received a B.S. in biology from Wuhan University in China and a Ph.D. in biology from Columbia University.

Mike **BOGDA**Christine **MUNDKUR**Timothy **SAWYER**

G. Frederick

WILKINSON**Barr Restructures Leadership**

Barr Pharmaceuticals, Montvale, N.J., has announced a number of promotions as part of

a restructuring of its senior management team to better align the company's global generic and proprietary businesses, optimize operations, and increase efficiencies across the organization worldwide.



Mike Bogda has been promoted to president and chief operating officer of Barr Laboratories, the company's generic pharmaceuticals business.

Mr. Bogda was previously Barr's executive VP, global product supply. He continues to oversee all aspects of global product supply, with additional responsibility for quality and pharmaceuticals.

Mr. Bogda received an M.S. in chemical engineering from Rutgers University and an MBA from the Wharton School of the University of Pennsylvania.



Christine Mundkur has been named CEO of Barr Laboratories, with responsibility for leading the global generics business. Most recently, Ms. Mundkur served as executive VP, global quality, safety, and regulatory

affairs at the company.

She holds a B.S. in chemistry from Saint Louis University and a J.D. from Saint Louis University School of Law.



Timothy Sawyer has been promoted to executive VP, global generic sales and marketing, with responsibility for Barr's generic commercial operations around the world. Mr. Sawyer was previously Barr's senior VP of

European commercial development.

He has a bachelor's degree from the University of Richmond.



G. Frederick Wilkinson has been promoted to the newly created position of CEO of Duramed Pharmaceuticals, the company's proprietary products business.

Mr. Wilkinson was previously president and chief operating officer of Duramed.

In addition to managing product selection, clinical development, and sales and marketing at Duramed, Mr. Wilkinson continues to direct Barr's growing global biologics development program.

He earned a B.S. in pharmacy from Ohio Northern University and an MBA from Capital University.

Dr. Gavin **CORCORAN****Stiefel Promotes Head of R&D**

Stiefel Laboratories, a dermatology specialty company based in Coral Gables, Fla., has promoted Gavin Corcoran, M.D., FACP, to chief scientific officer, a position created to reinforce the critical role played by the company's research and development organization and to further strengthen collaboration among Stiefel's five global R&D facilities. Dr. Corcoran was most recently senior VP, global research and development.

As chief scientific officer, Dr. Corcoran oversees global scientific and operational activities related to product development and support, medical and scientific affairs, clinical and preclinical research, pharmacovigilance, portfolio planning, and regulatory affairs. He received a medical degree from University of the Witwatersrand in Johannesburg, South Africa.

George **ESGRO****Cornerstone BioPharma Appoints Sales VP**

Cornerstone BioPharma, Cary, N.C., a specialty pharmaceutical company that focuses on the development and commercialization of prescription medications in the respiratory market, has named George Esgro VP of sales and marketing. A 20-year industry veteran, Mr. Esgro most recently was east regional sales director at Roche. He received a business degree from James Madison University.

Dr. Anthony **FOX****Conatus Selects Part-Time Medical Chief**

Conatus Pharmaceuticals has appointed Anthony Fox, M.D., Ph.D., as a part-time chief medical officer. Conatus, San Diego, is a specialty pharmaceutical company developing therapeutics to treat liver disease.

Dr. Fox's primary responsibility at Conatus is to oversee the recently initiated Phase II clinical trial of CTS-1027 in patients infected with the hepatitis C virus, as well as assisting with longer-term clinical development plans. In addition to this role, Dr. Fox continues to serve as president of EBD Consulting.

He has a bachelor's degree in pharmacology, earned his medical degree at the London Hospital (now Royal), and received a doctorate on quantitative drug-receptor interactions from the University of London.

Regulatory **POOL**

Dr. Frank **TORTI**

FDA Creates Chief Scientist Post



The U.S. Food and Drug Administration has appointed Frank Torti, M.D., MPH, principal deputy commissioner and the agency's first chief scientist.

In these roles, Dr. Torti is supporting the launch of the FDA Fellowship Program, which has the potential to attract up to 2,000 professionals of varying disciplines for a two-year training program.

The newly created position stems from the

Food and Drug Administration Amendments Act of 2007. The new office is working to ensure the quality and regulatory focus of the FDA's intramural research programs, with special emphasis on the importance of clinical research trials that are a part of the foundation of the FDA's regulatory structure.

A prominent clinician, scientist, and researcher in molecular oncology, Dr. Torti is currently serving as Charles L. Spurr professor of medicine, chair of the Department of Cancer Biology, and director of the Comprehensive Cancer Center at Wake Forest University School of Medicine.

He received his bachelor's and master's degrees from The Johns Hopkins University, his M.D. from Harvard Medical School, and his MPH from Harvard School of Public Health.

He currently serves on the National Institutes of Health's National Advisory Council for Complementary and Alternative Medicine.

Dr. Torti also founded and serves as President of the Cancer Biology Training Consortium.

Agency **POOL**

Erika **ANTONUCCI**

Eric **CALE**

Molly **LARSEN**

Michelle

SAMENFELD

Meredith Keroff

WEBER

AbelsonTaylor Expands Account Services

Independent healthcare advertising agency AbelsonTaylor, Chicago, has announced a number of appointments in its account services area.



Erika Antonucci has been promoted to senior account supervisor from account supervisor.

Ms. Antonucci continues to serve as the day-to-day strategic and tactical lead for an account in the sleep category at the

agency.

She received a B.S. in marketing and finance from Marquette University.



Eric Cale has joined AbelsonTaylor as account executive, with responsibility for a product for the treatment of GERD.

Mr. Cale was most recently an associate account executive at Williams Labadie.

He earned a B.S. in marketing from the Kelley School of Business, Indiana University.



Molly Larsen has been promoted to senior account executive from account executive.

Ms. Larsen has responsibility for managing accounts in the osteoporosis area.

She holds a B.A. in psychology from Northwestern University.

WYETH READIES FOR R&D SUCCESSION

Dr. Mikael **DOHLSTEN**

Dr. Robert R.

RUFFOLO JR.

Wyeth Names President of R&D

Wyeth, Madison, N.J., has announced that Robert R. Ruffolo, Jr., Ph.D., 58, will retire as president of Wyeth Research and senior VP, Wyeth, later this year. He will be succeeded by Mikael Dohlsten, M.D., Ph.D.

Dr. Ruffolo joined Wyeth in November 2000 and has been responsible for all pharmaceutical research and development (R&D) for the company, including discovery, drug safety and metabolism, chemical and pharmaceutical development, clinical R&D, and research operations.

Throughout his 31-year career in the pharmaceutical industry, Dr. Ruffolo's work has been recognized with a number of prestigious awards.

In March, he was recognized by the Pharmaceutical Research and Manufacturers of America (PhRMA) with the 2008 Discoverer's Award for his efforts in the discovery and development of Coreg while at GlaxoSmithKline.

The Wyeth Research and Development Executive Team (RADEX), formed and chaired by Dr. Ruffolo, won the 2006 Scrip Award for Management Team of the Year. In 2005, he won the George B. Koelle

Award for Scientific Excellence. In 2004, he was named Chief Scientific Officer of the Year by IBC Conferences.

Dr. Dohlsten, 49, previously was executive VP within pharmaceutical research and development/medicine at Boehringer Ingelheim. He was responsible for leading the company's worldwide pharmaceutical research in the United States, Canada, Germany, Italy, Austria, and Japan. In addition, he was a member of the corporate management team responsible for review-

ing all worldwide development projects and licensing opportunities.

Before joining Boehringer Ingelheim, Dr. Dohlsten spent more than 15 years in various leadership roles in pharmaceutical research, including positions with AstraZeneca and Pharmacia & Upjohn.

Dr. Dohlsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden.

He also studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as adjunct professor in immunology at the medical faculty in Lund.



Dr. Robert R. Ruffolo Jr.



Michelle Samenfeld has joined the agency as account executive, responsible for managing an account for the treatment of acid reflux.

Ms. Samenfeld was previously a senior account executive at Corbett Worldwide Health Communications.

She received a B.A. in journalism from the University of Wisconsin-Madison's School of Journalism and Mass Communication.



Meredith Keroff Weber has been promoted to senior account supervisor from account supervisor.

Ms. Weber has experience in a wide range of therapeutic categories, including infectious disease, allergic rhinitis, chronic idiopathic urticaria, allergic conjunctivitis, and overactive bladder.

She received a bachelor's of general studies in communications from the University of Kansas.

Stephen BINGHAM

JFK Communications Appoints VP

Healthcare public-relations firm JFK Communications, Princeton, N.J., has named Stephen Bingham VP, with responsibility for overseeing the agency's growing list of pharmaceutical, specialty pharma, and medical technology clients.

Mr. Bingham has 20 years of healthcare communications experience. Most recently, he was as a senior member of the Caunos Group. He previously ran his own firm, Bingham Associates.

Elizabeth CASTILLO

Derev DIGGS

Courtney HUTCHINS

Kevin KASZUBA

Shane MAYER

Buddy SCALERA

Qi Promotes and Expands Creative and Account Staff

Qi, a full-service digital agency and part of CommonHealth, has announced several promotions and additions to its creative and account teams.



At the Parsippany, N.J.-based agency Elizabeth Castillo has been promoted to group art supervisor of interactive media from her previous role as senior graphic designer.

Ms. Castillo's core responsibilities include the implementation of best practices in design, infrastructure architecture, application of animation, video, online branding, and social media marketing.



Derev Diggs has joined Qi as a senior interactive media developer.

Previously, Mr. Diggs was a senior multimedia developer at Temel, now known as Zeta Interactive.



Courtney Hutchins has joined Qi as an e-marketing associate from HLS, CommonHealth's founding medical-education unit.

In this role at Qi, Ms. Hutchins manages interactive content projects, monitors industry trends, and develops new marketing and advertising programs.



Kevin Kaszuba has been named a motion designer/video editor.

Before joining Qi, Mr. Kaszuba was a senior interactive designer at JDK Design.



Shane Mayer has been appointed an account supervisor, with responsibility for managing the tactical planning processes for interactive strategies, focusing on the development and implementation of marketing plans.

Mr. Mayer was most recently a senior marketing manager at WebMD.



Buddy Scalera has been promoted to VP, interactive content and market research, from senior director, interactive content and market research.

In this role, Mr. Scalera oversees the digital team and researches, develops, and delivers new interactive online strategies, including social and viral marketing, Web content,

search-engine marketing campaigns, and mobile applications.

Jason CHIN

Alla

LITOVCHENKO

Bruce MACINDOE

Matt THORSEN

Seidler Bernstein Adds to Creative Group

Seidler Bernstein, Cambridge, Mass., a full-service marketing communications agency specializing in healthcare and life technologies, has announced a number of additions to its creative team.



Jason Chin has joined Seidler Bernstein as interactive art director from Digitas, where he served as a senior design consultant.

Mr. Chin holds a BFA in industrial design from the Massachusetts College

of Art.



Alla Litovchenko has been promoted to associate creative director, art. Ms. Litovchenko has been with Seidler Bernstein since 2003 and is responsible for many of the agency's award-winning designs, including work

for Bayer Healthcare Diagnostics, Boston Scientific, GE, PerkinElmer, and Quest Diagnostics.

She is a graduate of the Academy of Arts School in Chernigov, Russia.



Bruce Macindoe has joined Seidler Bernstein as senior art director. Mr. Macindoe held the same position at the Pappas Group.

He holds a BFA in graphic design from the Norwich School of Art in the United Kingdom.



Matt Thorsen has joined the agency as director of creative services. A 20-year agency veteran, Mr. Thorsen has held a number of creative and production positions at agencies such as Arnold Worldwide, Philip Johnson Associates, and Orsatti and Partners.

Katherine **CUNDIFF**
 David **GOLDFARB**
 Chris **KEEFE**
 Karen **MELANSON**
 Peter **SIEGEL**


**Pacific Communications
 Makes Staff Changes**

Pacific Communications, Costa Mesa, Calif., has announced a number of promotions and additions to its account and creative teams.

Katherine Cundiff has joined Pacific as an account group supervisor for Allergan Medical Global. Ms. Cundiff was previously responsible for strategic planning, global launches, and account management at Mindshare Creative and was in charge of overseeing aesthetics accounts for CommuniQué Marketing.

David Goldfarb has been promoted to associate creative director/copy, responsible for the Allergan Therapeutics and Medical Dermatology accounts. Mr. Goldfarb has been with Pacific for three years.

Chris Keefe has been promoted to creative director/art. He has been with Pacific since 2002.



Karen Melanson has been promoted to VP director of client services, with responsibility for overseeing the Allergan Medical Dermatology, Medtronic, Advanced Sterilization Products/J&J, Inspire, and

Prometheus accounts.

Ms. Melanson has been with Pacific for 15 years and has been involved in nearly every client area for the agency.

Healthcare advertising veteran Peter Siegel has joined Pacific as executive creative director from the same position at The Hal Lewis Group.

Su **JANG**

Topin Adds Account Executive



Topin & Associates, a full-service healthcare advertising agency based in Chicago, has hired Su Jang as account executive working on the Baxter Global Medication Delivery account. Ms. Jang was most recently account manager at Siren Interactive.

Spring **MOORE**
 Daniel **SCHRIER**

**Avenue A | Razorfish Expands
 Philadelphia Office**

Interactive services agency Avenue A | Razorfish has added two members to its Philadelphia-based staff.



Spring Moore has joined as user experience lead, working with information architects, designers, and copywriters to develop interactive models. Ms. Moore was previously creative director at Solutions for Progress.



She received a B.A. in fine arts from the University of Pennsylvania.

Daniel Schrier was appointed senior project manager, leading Web development and interactive media projects. Mr. Schrier was most recently editorial systems project manager for Managing Editor (MEI). He holds a

B.A. in English creative writing from California State University, Hayward.

Sarah **PHILLIPS**
**Photosound Announces
 Promotion**



Photosound has promoted Sarah Phillips to senior account manager. Photosound, Plainsboro, N.J., part of the Health-Star Communications network of companies, is a medical communications and design agency

with offices in the United States, the United Kingdom, and France.

Marge **SUTPHEN**
 Jonathan **WOOD**

**Centron Adds Creative,
 Account Staff**

Centron, New York, has announced two additions to its creative and account teams. Marge Sutphen has joined Centron as VP, account group supervisor. Ms. Sutphen previously worked at Grey Healthcare. Jonathan Wood has joined the agency as creative group supervisor, from copy group supervisor at Euro RSCG Life MetaMax.

Paul **VENTURA**

EPIC Brand Adds Account Exec



EPIC Brand Communications, Aliso Viejo, Calif., has appointed Paul Ventura account executive. With extensive career experience in a wide range of medical products and therapeutics for major pharmaceutical companies, Mr. Ventura was previously a senior sales specialist for Eli Lilly and a field sales representative for Merck and Ross Laboratories, a division of Abbott Laboratories.

CRO POOL

Sharon **DINKINS**

**CRI Worldwide Expands
 Regulatory Group**

CRI Worldwide, Clementon, N.J., has appointed Sharon Dinkins to the newly created position of director of quality assurance and regulatory affairs. Ms. Dinkins has more than 30 years of experience, most recently as director, quality assurance, North America at MDS Pharma Services. She received a B.S. in criminal justice from Temple University.

Media POOL

Dr. Charles **NEMEROFF**

**New Editor at Quadrant
 HealthCom Journal**



Medical journal publisher Quadrant HealthCom, Parsippany, N.J., has named Charles Nemeroff, M.D., Ph.D., editor-in-chief of *Neuro-Psychiatry Reviews*, a monthly clinical news tabloid focused on the biological basis of psychiatry.

Dr. Nemeroff received a master's degree in biology from Northeastern University and an M.D. and Ph.D. in neurobiology from the University of North Carolina at Chapel Hill.

Medical-Education POOL

Laura **AIBARA**

Dr. Robin **SMITH**

Staff Changes at Curry Rockefeller

The Curry Rockefeller Group (CRG), New York, has added two staff members to its medical-education programming and editorial teams.

Laura Aibara joins CRG as program director. She most recently was program manager at Haymarket Medical. She received a B.A. in communications and advertising from Iona College.



CRG has appointed Robin Smith, Ph.D., scientific director. Dr. Smith is responsible for assisting in the development of strategic publication planning and implementation.



Dr. Smith was previously senior executive editor, sciences, at Columbia University Press. He received a B.S. with honors in cell and molecular biology from King's College at the University of London and a Ph.D. in biochemistry from the

University of Cambridge's Medical Research Council Laboratory of Molecular Biology.

Service POOL

Randi **BOGARD**

Matt **GLAVAS**

Richard "Tex" **KUND**

Sidhartha **RAO**

Algis "Al" **SALCIUNAS**

Clement **SMITH**

MTI Adds to Staff

MTI, a provider of pharmaceutical marketing products in Langhorne, Pa., has made several additions to its staff. Randi Bogard

has been appointed VP, business development.

In this position, Ms. Bogard is responsible for fostering existing client relationships, promoting MTI's pharmaceutical marketing products, and developing new business opportunities that support the company's growth strategy.

Before joining MTI, Ms. Bogard worked with Lathian Systems as regional sales VP. She is a graduate of Florida State University where she earned a bachelor of science in communications.

MTI has hired Matt Glavas as director, business analytics. He is responsible for leading MTI's business analytics team in the use of advanced statistical methodologies to generate, interpret, and present market analysis used in support of MTI's marketing programs.

Mr. Glavas has more than 18 years of professional experience, seven of which were at Bristol-Myers Squibb. He earned his master's in business administration from the University of North Carolina and his bachelor's degree from the University of California.

MTI has appointed Richard "Tex" Kund as VP, business development. Mr. Kund is responsible for fostering existing client relationships, promoting MTI's pharmaceutical marketing products and developing new busi-

ness opportunities that support the company's growth strategy.

Before joining MTI, Mr. Kund held the position of director of business development for PDI, where he was responsible for identifying potential new business within the biopharmaceutical industry. Mr. Kund attended St. Vincent College in Latrobe, Pa., and earned a bachelor's degree in business administration from Temple University.

MTI has hired Sidhartha Rao as director, systems. In this position, Mr. Rao is responsible for developing and managing strategic plans for MTI's technology infrastructure.

Before joining MTI, Mr. Rao worked with Ranbaxy as chief technology architect and security officer. He received a bachelor of science degree from Delhi University, Delhi, India.


MTI has hired Algis "Al" Salciunas as director, product management. In this position, Mr. Salciunas is responsible for maintaining and managing product concepts, product business models and all commercial aspects of MTI's cornerstone marketing product, Extender.

Before joining MTI, Mr. Salciunas spent nearly 16 years at IMS Health, most recently holding the position of business/competitive intelligence principal.

He earned a master's in business adminis-

Pharma **VOICE**
MarketPlace.com

More than 5,500 Solutions Providers



The most comprehensive online directory of products and services for the life-sciences industry — featuring a wide range of products, services, and solutions for your clinical, commercial, business, and technology needs.

Browse by Category • Search by Company

tration, specializing in marketing and bachelor of arts in English and journalism from Rutgers University.

Additionally, Clement Smith has been appointed VP, business development. Mr. Smith is responsible for fostering existing client relationships, promoting MTI's pharmaceutical marketing products, and developing new business opportunities that support the company's growth strategy.

Before joining MTI, Mr. Smith worked with Princeton Softech as an account executive and was recognized for numerous accomplishments.

He earned a bachelor of arts in communications from The College of New Jersey.

John CARRO

James CASTELLO

TGaS Hires Industry Veterans Amid Expansion



TGaS Advisors, an East Norriton, Pa.-based benchmarking company focused on pharmaceutical commercial operations, has named John Carro VP, management advisor.

Mr. Carro is part of the company's sales/sales operations practice and is responsible for existing services as well as developing innovative new solutions for clients. He was most recently VP, commercial operations, at King Pharmaceuticals.

TGaS also has appointed James Castello director, management advisor, in the company's sales operations practice.

Mr. Castello was previously managing director at Syngy. He received a bachelor's degree in finance and an MBA from Pennsylvania State University.

Diana CRAWLEY

Publicis Selling Solutions Names Director of New Division



Publicis Selling Solutions, a Lawrenceville, N.J.-based provider of sales teams and support services to the biopharmaceutical industry, has appointed Diana Crawley executive director of Publicis Clinical Health Partners, a new division that provides integrated, behaviorally based education programs designed to optimize patient compliance and treatment outcomes.

Publicis Selling Solutions is part of the

Publicis Selling Solutions Group, a Publicis Healthcare Communications Group company.

Ms. Crawley has 18 years of leadership and healthcare experience and six years of industry experience leading clinical health educator teams. Before joining Publicis Selling Solutions Group, she was a project leader at a company that also provides health educator teams.

She earned a B.S. in nursing from the University of Florida and an MBA from Indiana Wesleyan University.

Darren HEAD

Cytovance Announces New CEO



Cytovance Biologics, an Oklahoma City-based biopharmaceutical contract manufacturing organization specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, has named

Darren Head CEO.

Mr. Head previously served as VP of worldwide operations for Immucor, where he served as VP of worldwide operations, overseeing the manufacturing of biological products in the United States, Europe, and Canada.

Dr. Aaron KANTOR

ITI Expands Management Team

The Immune Tolerance Institute (ITI) has selected Aaron Kantor, Ph.D., as its chief scientific officer. ITI is a San Francisco-based nonprofit founded in partnership with the University of California, San Francisco (UCSF) to translate fundamental scientific discoveries into new therapies for a broad range of diseases related to the human immune system.

Most recently, Dr. Kantor served as executive director of cell and molecular biology for biomarker discovery sciences at Pharmaceutical Product Development (PPD).

He received a bachelor's degree in biophysics from the University of Pennsylvania and a Ph.D. in biophysics from the University of California at Berkeley.

Eva LAPARRA

Jonathan SPIESS

Ziment Expands Marketing, Technology Leadership

Healthcare marketing research and consulting organization Ziment Group, New

York, has announced the appointment of two executives to lead its groupwide marketing and technology activities.

This expansion reflects the rapid growth of Ziment Group's four companies: Ziment Custom, the strategic primary marketing research division; imap Research, which provides syndicated market tracking research; Consumer Health Sciences (CHS), which conducts the National Health and Wellness Survey, a leading disease-specific consumer survey; and All Global, the market leader in global healthcare data collection.

Eva Laparra has been named VP, marketing of Ziment Group, responsible for marketing and communications programs for all group companies.

Ms. Laparra is a founder and former director of All Global, which merged with Ziment's WebSurveyResearch business in March.

She holds a B.S. in business management and an M.S. in international business.

Jonathan Speiss has joined Ziment Group as VP, technology and innovation, with responsibility for providing state-of-the-art technology solutions that advance operations, marketing, and product development across all group companies.

Mr. Speiss has more than 20 years of business technology experience, during which he has held management positions in technology and R&D with major pharmaceutical companies such as Bristol-Myers Squibb and Johnson & Johnson.

He also was founder, principal, and chief technology officer of Digital Resolutions, a digital marketing company.

Mr. Speiss received a B.S. from the Rochester Institute of Technology and an MBA from the University of Phoenix.

Tammy PENKALSKI

GCG Event Partners Names Business Development Manager



Tammy Penkalski has joined GCG Event Partners as manager of business development.

GCG Event Partners, Stoneham, Mass., is a supplier to the meeting planning industry with a focus on both CME and non-

CME medical meetings, particularly pharmaceutical dinner meetings.

Ms. Penkalski was most recently manager of operations for a private CME company. She attended Eastern Kentucky University. ♦

Send your personnel announcements to feedback@pharmavoices.com.